42 results on '"Mian, O.Y."'
Search Results
2. Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node Positive Prostate Cancer: A Multi-Institutional Study
3. Recursive Partitioning Analysis to Define Prognostic Groups Using a Large Single Institution Experience of Multimodality Radiation Therapy for Bladder Cancer
4. Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate
5. Prostate Cancer Screening Disparities in Persons Experiencing Homelessness
6. Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003
7. Identification of Putative Gene-Target Modulators of Radiosensitivity in Bladder Cancer Cell Lines (BlaCCL)
8. Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based neoadjuvant chemotherapy
9. Feasibility of Ultrasound-Based Intra-Fraction Motion Monitoring for Prostate Stereotactic Body Radiation Therapy
10. 125I Interstitial Brachytherapy with or without Androgen Deprivation Therapy among Unfavorable Risk Prostate Cancer
11. Transcriptomic and Mutational Analyses Identify Biological Processes Correlated with Bladder Cancer Cell Line (BlaCCL) Radiation Response
12. A Common Polymorphism in 3β-hydroxysteroid Dehydrogenase Promotes Resistance to Radiotherapy
13. Evaluating the 2018 NCCN Classification System for Intermediate-risk Prostate Cancer Patients Undergoing External-beam Radiation Therapy
14. Monitoring Intra-Fraction Prostate Motion Using Kv Triggered Imaging during SBRT
15. A Comparison between External Beam Radiotherapy and Low Dose-Rate Brachytherapy for Definitive Treatment of Gleason 9&10 (ISUP 5) Prostate Cancer
16. Validation of the 2018 NCCN Prostate Cancer Risk Classification among 2,715 Patients Treated with Low Dose Rate I-125 Brachytherapy
17. Impact of Cribriform Pattern 4 and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy
18. Molecular characterization of neuroendocrine-like bladder cancer
19. The Effect of the Timing of Biochemical Failure after External Beam Radiation Therapy or Low Dose-rate Brachytherapy for Definitive Prostate Cancer Treatment
20. Ten-Year Outcomes and Toxicity with Moderately Hypofractionated (70 Gy in 28 fractions) Intensity-Modulated Radiation Therapy for Localized Prostate Cancer.
21. Hydroxyflutamide Induces Androgen Receptor-Mediated DNA Damage and Radiosensitizes Prostate Cancer Cells While Preventing Induction of Pro-Growth Programs
22. Tumor Gene Expression Profiling in Prostate Cancer (PCa) Identifies Molecular Taxonomies Associated with Node Positivity and Quantitative Imaging Features on Multiparametric MRI (mpMRI)
23. Achieving “Zero PSA” Following Post-Prostatectomy Radiation Therapy for Lymph Node Positive Prostate Cancer in the Ultrasensitive PSA Era
24. Stereotactic Body Radiation Therapy in Pancreas Adenocarcinoma Demonstrates Minimal Acute and Late Toxicity
25. Molecular Profiling of Small Cell Bladder Cancer Reveals Gene Expression Determinants of an Aggressive Phenotype
26. Prostate SBRT Intrafraction Monitoring With Transperineal Ultrasound
27. A Prospective Study Evaluating Registered Ultrasound and Fluoroscopy (RUF) for Intraoperative Dose Calculation: Improved Accuracy Compared to Current Ultrasound-based Intraoperative Dosimetry
28. Neoadjuvant Stereotactic Body Radiation Therapy Dosimetric Parameters Predict for Pathologic Outcomes and Survival in Pancreas Adenocarcinoma
29. Volumetric Assessment of Tumor Vessel Interaction Is a Predictor of Surgical Candidacy in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Treated With Stereotactic Body Radiation Therapy
30. Pancreas Stereotactic Body Radiation Therapy Demonstrates Minimal Acute Treatment-Related Toxicity
31. Partial Agonist Activity of Hydroxyflutamide Induces AR- and TOP2B-dependent DNA Double Strand Breaks and Radiosensitizes Prostate Cancer Cells
32. Reductions in Prostatic and Urethral Doses Are Associated With Less Acute Morbidity in Patients Undergoing Pd-103 Brachytherapy: Substantiation of the Rationale for Focal Therapy
33. 477 - Molecular characterization of neuroendocrine-like bladder cancer
34. Generation of DNA Double Strand Breaks in Prostate Cancer Cells by Androgen Receptor Antagonists, Hydroxyflutamide and Bicalutamide
35. Dosimetric Predictors of Sexual Function Decline Following Low-Dose-Rate Brachytherapy for Prostate Cancer (PCa)
36. Dosimetric Parameters Correlate With Node Negative Resection in Borderline and Initially Unresectable Pancreatic Adenocarcinoma Patients Treated With Stereotactic Body Radiation Therapy Followed by Surgical Resection
37. Total Lesion Glycolysis as a Predictor of Pathologic Outcomes Locally Advanced and Borderline Resectable Patients Undergoing Surgery After Preoperative Stereotactic Body Radiation Therapy
38. A Novel Technology for Noninvasive Detection of Prostate Cancer DNA in the Blood and Urine of Men With High-Risk PCA Receiving Radiation Therapy and Androgen Suppression
39. Dosimetric Parameters Predicting Late Toxicity in Stereotactic Body Radiation Therapy (SBRT) for Pancreatic Cancer
40. Reduced Lymphocytopenia Following Stereotactic Body Radiation Therapy (SBRT) for Spine Metastases Compared With Conventional Radiation Therapy (CRT)
41. Preference to Spare Critical Anatomy Near Gross Tumor Volume Is Associated With Poor Pathologic Complete Response With Breath Hold–Based Neoadjuvant Stereotactic Body Radiation Therapy for Pancreatic Cancer
42. Timely Radiosurgery for Spine Metastases per RTOG 0613 Guidelines Using a Rapidly Deployable Automated Planning Script
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.